We’re building on the success of Dupixent® in atopic dermatitis and asthma, developing new solutions for people with debilitating immuno-dermatological, rheumatic, respiratory, and gastrointestinal diseases.
Scaling up innovation
We partner with companies that bring cutting-edge technologies and transformative assets in immuno-inflammation. We bring expertise in biological pathways, research-enabling technologies, proven precision-medicine approaches to clinical development, and robust commercial organization.
Partnering success stories
This global collaboration produced Dupixent®, a novel biologic approved for atopic dermatitis, severe asthma, and eosinophilic esophagitis, and in development for a range of additional potential indications.
In partnership with Kymera, we develop and commercialize first-in-class protein degrader therapies that target IRAK4 in patients with immuno-inflammatory diseases.
We’re working on a CD40L monoclonal antibody (INX-021) initially developed by ImmuNext, as a treatment for autoimmune diseases including lupus and multiple sclerosis.
Your partnering leads in Immunology
For more information, contact us at email@example.com
Head of External Innovation, Immunology
Global Head of Business Development, Immunology